Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models
暂无分享,去创建一个
D. Holtzman | S. Paul | R. Crystal | S. Kaminsky | Lingzhi Zhao | M. J. Chiuchiolo | P. Sullivan | D. Sondhi | Mayur S. Parmar | Mingjie Li | A. Gottesdiener | Maria J. Chiuchiolo
[1] V. Pankratz,et al. Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease , 2015, Neurobiology of Aging.
[2] J. Hardy,et al. Apolipoprotein E in Alzheimer's disease: an update. , 2014, Annual review of neuroscience.
[3] Verena Heise,et al. The forgotten APOE allele: A review of the evidence and suggested mechanisms for the protective effect of APOE ɛ2 , 2013, Neuroscience & Biobehavioral Reviews.
[4] B. Hyman,et al. Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain , 2013, Science Translational Medicine.
[5] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[6] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[7] Michael W. Weiner,et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study , 2013, Molecular Psychiatry.
[8] Jie Li,et al. Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms*♦ , 2012, The Journal of Biological Chemistry.
[9] D. Holtzman,et al. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.
[10] E. Weeber,et al. APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease* , 2012, The Journal of Biological Chemistry.
[11] K. Purpura,et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. , 2012, Human gene therapy methods.
[12] Guojun Bu,et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[13] D. Holtzman,et al. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.
[14] David M Holtzman,et al. Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.
[15] K. Bales,et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment , 2011, Neurobiology of Aging.
[16] M. Sandberg,et al. AAV-Mediated Gene Delivery in Adult GM1-Gangliosidosis Mice Corrects Lysosomal Storage in CNS and Improves Survival , 2010, PloS one.
[17] E. Masliah,et al. Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.
[18] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[19] D. Holtzman,et al. The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.
[20] F. Liu,et al. Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.
[21] C. Wellington,et al. Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E , 2009, BioFactors.
[22] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[23] F. Liu,et al. Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism , 2009, The Journal of Neuroscience.
[24] D. Yin,et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex , 2009, Proceedings of the National Academy of Sciences.
[25] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[26] J. Wolfe,et al. A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease , 2007, The Journal of Neuroscience.
[27] D. Peterson,et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[29] K. Weisgraber,et al. Apolipoprotein E structure: insights into function. , 2006, Trends in biochemical sciences.
[30] Inder M Verma,et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] W. Hauswirth,et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.
[32] A. Fagan,et al. Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.
[33] Xianlin Han,et al. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice , 2001, Neurochemistry International.
[34] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[35] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[37] N. Maeda,et al. Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.
[38] R. Motter,et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .
[39] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[40] N. Craddock,et al. Protection against Alzheimer's disease with apoE ∈2 , 1994, The Lancet.
[41] A. M. Saunders,et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.
[42] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[43] B. Hyman,et al. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.
[44] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[45] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Taylor,et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. , 1985, The Journal of clinical investigation.
[47] E. Masliah,et al. Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.
[48] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[49] L. J. Eldik,et al. ApoE and Aβ1–42 interactions , 2007, Journal of Molecular Neuroscience.
[50] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[51] L. V. Van Eldik,et al. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. , 2004, Journal of molecular neuroscience : MN.
[52] C. Kessler,et al. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. , 2000, Acta neuropathologica.
[53] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.
[54] K. Johnson-wood,et al. Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease (PDAPP mouseyb-peptideyamyloidogenesis) , 1997 .
[55] N. Craddock,et al. PROTECTION AGAINST ALZHEIMER'S DISDEASE WITH APOE EPSILON 2 , 1994 .
[56] M A Pericak-Vance,et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.